Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2. (Q54067573)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2. |
scientific article |
Statements
Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2. (English)
Keilholz U
Szelényi H
Siehl J
Foss HD
Knauf W
Thiel E
1 November 1999
35
5-6
641-642